Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BORTEZOMIB Cause Chronic kidney disease? 97 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 97 reports of Chronic kidney disease have been filed in association with BORTEZOMIB (bortezomib). This represents 0.2% of all adverse event reports for BORTEZOMIB.

97
Reports of Chronic kidney disease with BORTEZOMIB
0.2%
of all BORTEZOMIB reports
26
Deaths
38
Hospitalizations

How Dangerous Is Chronic kidney disease From BORTEZOMIB?

Of the 97 reports, 26 (26.8%) resulted in death, 38 (39.2%) required hospitalization, and 9 (9.3%) were considered life-threatening.

Is Chronic kidney disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BORTEZOMIB. However, 97 reports have been filed with the FAERS database.

What Other Side Effects Does BORTEZOMIB Cause?

Plasma cell myeloma (6,683) Off label use (4,754) Neuropathy peripheral (4,067) Drug ineffective (2,730) Diarrhoea (2,244) Thrombocytopenia (2,082) Death (2,025) Pneumonia (2,020) Fatigue (1,757) Neutropenia (1,530)

What Other Drugs Cause Chronic kidney disease?

OMEPRAZOLE (35,759) ESOMEPRAZOLE (35,281) LANSOPRAZOLE (32,517) PANTOPRAZOLE (28,127) DEXLANSOPRAZOLE (15,973) EMTRICITABINE\TENOFOVIR DISOPROXIL (10,248) TENOFOVIR DISOPROXIL (7,230) EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL (5,861) RABEPRAZOLE (4,773) ESOMEPRAZOLE\NAPROXEN (2,714)

Which BORTEZOMIB Alternatives Have Lower Chronic kidney disease Risk?

BORTEZOMIB vs BOSENTAN BORTEZOMIB vs BOSENTAN\BOSENTAN BORTEZOMIB vs BOSULIF BORTEZOMIB vs BOSUTINIB BORTEZOMIB vs BOTOX

Related Pages

BORTEZOMIB Full Profile All Chronic kidney disease Reports All Drugs Causing Chronic kidney disease BORTEZOMIB Demographics